# Study of IMC-P115C in Advanced PRAME-Positive Cancers

> **NCT07156136** · PHASE1 · RECRUITING · sponsor: **Immunocore Ltd** · enrollment: 140 (estimated)

## Conditions studied

- PRAME Positive
- Cancer
- HLA-A*02:01-positive

## Interventions

- **DRUG:** IMC-P115C

## Key facts

- **NCT ID:** NCT07156136
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-08-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07156136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07156136, "Study of IMC-P115C in Advanced PRAME-Positive Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07156136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*